David Aggen is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 172 publications with 2,232 citations (h-index 22); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
353 E 68th St
New York, NY 100655606
Telephone
646-422-4679Provider last certified this registry record 4 Aug 2022.
Clinical trials
- Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20251 payment
- Eisai Inc.Program year20253 payments
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
32.7%Corticosteroid18.1%Prednisone100%Part D≥25 patientsSerotonin-3 Receptor Antagonist10.7%Ondansetron Hcl100%Part D≥39 patients+ 1 more class in this area
Cancer & immunology
31.3%Kinase inhibitor23.5%Cabometyx36%Inlyta24%Everolimus18%Lenvima11%Fotivda11%Part D<11 patientsCytochrome P450 17A1 Inhibitor4.5%Abiraterone Acetate100%Part D<11 patients+ 1 more class in this area
Sensory organs
11.6%Corticosteroid11.6%Dexamethasone58%Dexamethasone Sodium Phosphate42%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
Journal of Clinical Oncology
2025 - Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
Nature Communications
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”